Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/780366

Contents of this Issue

Navigation

Page 39 of 47

In the Lab 38 Clinical OMICs January/February 2017 www.clinicalomics.com of a patient's cancer," added Gerald J. Vardzel, Jr., Helomics president and CEO. med fusion Adds HemeSEQ Hematologic Neoplasm Profiles to Testing Services Laborator y ser vices company med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, announced an expansion of its oncol- ogy testing services to include the new HemeSEQ portfolio of next-generation sequencing (NGS) profiles covering four hematologic neoplasms: acute myeloid leukemia (AML Profile), chronic lympho- cytic leukemia (CLL Profile), diffuse large B-cell lymphoma (DLBCL P r o f i l e ) and myeloproliferative neoplasms (MPN Profile). Understanding the pathobiology of hematologic diseases and the effective management of patients with these diseases depends on data from accu- rate molecular diagnostic tests. To help meet this need, med fusion developed the HemeSEQ profiles which expand its hematologic menu to nearly 100 tests, and incorporate NGS technology to more thoroughly interrogate the genetic basis of a patient's disease. "Our ultimate goal at med fusion is to help improve patient care," said Jon Hart, CEO of med fusion. "We believe the best way to accomplish this is by providing physicians with responsible precision medicine tools that deliver actionable results quickly. Our new hema- tologic neoplasm profiles exemplify our a p p r o a c h , a n d we look forward to their contribution to patient care for patients with AML, CLL, DLBCL, and MPN." LifeLabs Picks Transgenomic's Platform for Mutation Enrichment Cancer and rare disease diagnostic company Transgenomic reported that Canadian laboratory services provider LifeLabs has selected its ICE COLD-PCR (ICP) technology as its mutation-enrich- ment platform for cancer testing. "LifeLabs is committed to offering our customers access to advanced clin- ical genomic analyses made possible by major new technologies such as ICE COLD-PCR," said LIfeLabs' Joby McKen- zie, senior vp, business development. "We anticipate that this flexible, versatile mutation enrichment technology will be applied to other molecular testing appli- cations as adoption of genomic and pre- cision medicine expands." LifeLabs operates more than 360 patient service centers in Ontario and British Columbia. n In the Lab (continued from page 36) The number one magazine for translational researchers and healthcare leaders involved in the transfer of omics technologies in clinical diagnostics Exclusive coverage on hot topics including: • Genomic testing and analysis • Applications of omics research • Liquid biopsies/noninvasive diagnostics • Precision medicine • Companion diagnostics • Clinical practice • Big data/informatics researchers and healthcare leaders involved in the transfer of omics technologies in clinical diagnostics transfer of omics technologies in clinical diagnostics Join thousands of dedicated healthcare professionals looking transform patient care DON'T MISS AN ISSUE Get your FREE subscription: ClinicalOMICs.com/subscription Benchamat1234 / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017